Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 2/20 | 0.31 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056060 | 0.90 | PDE3A (0.37) | PDE3AALDH1A1LMNAPDE10ATLR9 | |
| SCHEMBL3042342 | 0.89 | NTSR1 (0.35) | ALDH1A1LMNAPDE10ATLR9TLR8 | |
| SCHEMBL3055966 | 0.89 | PDE3A (0.41) | PDE3AALDH1A1LMNAPDE10ATLR9 | |
| SCHEMBL3059879 | 0.87 | PDE10A (0.46) | PDE3AALDH1A1LMNAPDE10ATLR9 | |
| SCHEMBL3056642 | 0.87 | PDE3A (0.40) | PDE3AALDH1A1LMNAPDE10ATLR9 | |
| SCHEMBL3047030 | 0.80 | PRKDC (0.46) | PDE3AALDH1A1LMNAPDE10APRKDC | |
| SCHEMBL3056007 | 0.80 | ALDH1A1 (0.43) | PDE3AALDH1A1LMNAPDE10APRKDC | |
| SCHEMBL3050044 | 0.79 | PDE3A (0.39) | PDE3AALDH1A1LMNAPDE10A | |
| SCHEMBL3059818 | 0.79 | PRKDC (0.49) | PDE3AALDH1A1LMNAPDE10APRKDC | |
| SCHEMBL3058117 | 0.78 | PDE3A (0.40) | PDE3AALDH1A1LMNAPDE10ANTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-09-02 | — | — | US | claimed |
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PDE12, PDE5A, PDE2A | PDE3A 5/4885ALDH1A1 997/4885LMNA 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.